Clinical experiment designed to assess clinical efficacy targeting LPS in human. Primary outcome: Change in plasma LPS levels and gut microbiome alpha diversity (Shannon index) from baseline to 6 mo
Description
Microbiome-Gut-Brain Axis in Alzheimer's Disease — mechanism and intervention
Background and Rationale
The microbiome-gut-brain axis represents a bidirectional communication network between the gastrointestinal tract and central nervous system, mediated by neural, hormonal, and immunological pathways. Emerging evidence suggests that gut microbiome dysbiosis contributes to Alzheimer's disease (AD) pathogenesis through multiple mechanisms, including increased intestinal permeability, systemic inflammation, and altered production of neuroactive metabolites. Lipopolysaccharide (LPS), a bacterial endotoxin from gram-negative bacteria, serves as a key inflammatory trigger that can breach the blood-brain barrier and promote neuroinflammation characteristic of AD. This study employs a longitudinal, multi-site clinical trial design to investigate the mechanistic role of the gut-brain axis in AD progression and evaluate targeted microbiome interventions. We will recruit 300 participants across three groups: early-stage AD patients (n=100), mild cognitive impairment (MCI) patients (n=100), and cognitively healthy controls (n=100)....
Microbiome-Gut-Brain Axis in Alzheimer's Disease — mechanism and intervention
Background and Rationale
The microbiome-gut-brain axis represents a bidirectional communication network between the gastrointestinal tract and central nervous system, mediated by neural, hormonal, and immunological pathways. Emerging evidence suggests that gut microbiome dysbiosis contributes to Alzheimer's disease (AD) pathogenesis through multiple mechanisms, including increased intestinal permeability, systemic inflammation, and altered production of neuroactive metabolites. Lipopolysaccharide (LPS), a bacterial endotoxin from gram-negative bacteria, serves as a key inflammatory trigger that can breach the blood-brain barrier and promote neuroinflammation characteristic of AD. This study employs a longitudinal, multi-site clinical trial design to investigate the mechanistic role of the gut-brain axis in AD progression and evaluate targeted microbiome interventions. We will recruit 300 participants across three groups: early-stage AD patients (n=100), mild cognitive impairment (MCI) patients (n=100), and cognitively healthy controls (n=100). The study combines comprehensive microbiome profiling using 16S rRNA sequencing and shotgun metagenomics, measurement of gut permeability biomarkers including serum LPS and zonulin, neuroimaging assessments, and cognitive testing over 24 months. A nested interventional component will randomize 150 participants to receive either a targeted probiotic formulation designed to reduce LPS-producing bacteria or placebo for 12 months. Key innovations include the integration of multi-omics approaches (microbiome, metabolomics, proteomics) with advanced neuroimaging and the first targeted microbiome intervention specifically designed to modulate LPS-mediated neuroinflammation in AD. This research addresses a critical knowledge gap in AD etiology and may identify novel therapeutic targets for disease modification through microbiome manipulation.
This experiment directly tests predictions arising from the following hypotheses:
Gut Barrier Permeability-α-Synuclein Axis Modulation
Vagal Afferent Microbial Signal Modulation
Microbial Inflammasome Priming Prevention
Enteric Nervous System Prion-Like Propagation Blockade
Experimental Protocol
Phase 1 (Months 1-6): Recruit 300 participants meeting inclusion criteria through memory clinics and community screening. Collect baseline samples including fecal specimens for microbiome analysis (16S rRNA sequencing, shotgun metagenomics), blood samples for LPS, zonulin, inflammatory cytokines (IL-6, TNF-α, CRP), and AD biomarkers (Aβ42, tau, p-tau). Perform comprehensive cognitive assessment using ADAS-Cog, MMSE, and MoCA scales. Conduct structural MRI and PET imaging for amyloid and tau burden. Phase 2 (Months 7-12): Randomize subset of 150 participants to interventional arm receiving either multi-strain probiotic containing Lactobacillus helveticus R0052, Bifidobacterium longum R0175, and Lactobacillus rhamnosus R0011 (10^9 CFU daily) or matched placebo. Continue monthly monitoring of all participants with abbreviated assessments. Phase 3 (Months 13-18): Mid-study comprehensive reassessment replicating baseline measures. Analyze interim microbiome changes and LPS levels to assess intervention efficacy. Phase 4 (Months 19-24): Complete intervention period and final comprehensive assessment. Perform statistical analysis using linear mixed-effects models to evaluate longitudinal changes in microbiome composition, LPS levels, cognitive function, and neuroimaging biomarkers. Sample size calculations based on 80% power to detect 0.4 effect size difference in LPS levels between groups (α=0.05).
Expected Outcomes
AD patients will exhibit significantly reduced microbiome diversity (Shannon index 20-30% lower, p<0.01) and increased abundance of LPS-producing Enterobacteriaceae compared to controls
Serum LPS levels will be 2-3 fold higher in AD patients versus controls (mean difference >150 pg/mL, p<0.001) and correlate positively with cognitive decline (r>0.4, p<0.01)
Probiotic intervention will reduce serum LPS by 25-40% from baseline (p<0.05) and slow cognitive decline by 30% compared to placebo group as measured by ADAS-Cog scores
Gut permeability markers (zonulin) will correlate with brain amyloid burden on PET imaging (r>0.3, p<0.05) and predict cognitive decline over 24 months
Microbiome metabolomic analysis will identify 15-25 differentially abundant metabolites in AD patients, including reduced short-chain fatty acids and increased trimethylamine N-oxide
Intervention responders (>20% LPS reduction) will show preserved hippocampal volume and improved connectivity in default mode network on follow-up neuroimaging
Success Criteria
• Establish significant association between gut dysbiosis patterns and AD diagnosis with area under ROC curve >0.75 for microbiome-based classification model
• Demonstrate statistically significant correlation (p<0.01) between serum LPS levels and cognitive performance across all study timepoints
• Achieve primary endpoint of ≥25% reduction in LPS levels in probiotic group compared to placebo at 12 months with p<0.05
• Show significant between-group difference (p<0.05) in rate of cognitive decline favoring probiotic intervention by ≥2 points on ADAS-Cog scale
• Identify at least 10 bacterial species significantly associated with AD status (FDR-corrected p<0.05) that replicate across validation cohorts
• Demonstrate mechanistic pathway linking specific microbial taxa to LPS production, systemic inflammation, and neuroinflammation biomarkers with effect sizes >0.3
TARGET GENE
LPS
MODEL SYSTEM
human
ESTIMATED COST
$7,500,000
TIMELINE
58 months
PATHWAY
N/A
SOURCE
wiki
PRIMARY OUTCOME
Change in plasma LPS levels and gut microbiome alpha diversity (Shannon index) from baseline to 6 months, correlated with cognitive performance measured by ADAS-Cog scores.
Phase 1 (Months 1-6): Recruit 300 participants meeting inclusion criteria through memory clinics and community screening. Collect baseline samples including fecal specimens for microbiome analysis (16S rRNA sequencing, shotgun metagenomics), blood samples for LPS, zonulin, inflammatory cytokines (IL-6, TNF-α, CRP), and AD biomarkers (Aβ42, tau, p-tau). Perform comprehensive cognitive assessment using ADAS-Cog, MMSE, and MoCA scales. Conduct structural MRI and PET imaging for amyloid and tau burden. Phase 2 (Months 7-12): Randomize subset of 150 participants to interventional arm receiving either multi-strain probiotic containing Lactobacillus helveticus R0052, Bifidobacterium longum R0175, and Lactobacillus rhamnosus R0011 (10^9 CFU daily) or matched placebo.
...
Phase 1 (Months 1-6): Recruit 300 participants meeting inclusion criteria through memory clinics and community screening. Collect baseline samples including fecal specimens for microbiome analysis (16S rRNA sequencing, shotgun metagenomics), blood samples for LPS, zonulin, inflammatory cytokines (IL-6, TNF-α, CRP), and AD biomarkers (Aβ42, tau, p-tau). Perform comprehensive cognitive assessment using ADAS-Cog, MMSE, and MoCA scales. Conduct structural MRI and PET imaging for amyloid and tau burden. Phase 2 (Months 7-12): Randomize subset of 150 participants to interventional arm receiving either multi-strain probiotic containing Lactobacillus helveticus R0052, Bifidobacterium longum R0175, and Lactobacillus rhamnosus R0011 (10^9 CFU daily) or matched placebo. Continue monthly monitoring of all participants with abbreviated assessments. Phase 3 (Months 13-18): Mid-study comprehensive reassessment replicating baseline measures. Analyze interim microbiome changes and LPS levels to assess intervention efficacy. Phase 4 (Months 19-24): Complete intervention period and final comprehensive assessment. Perform statistical analysis using linear mixed-effects models to evaluate longitudinal changes in microbiome composition, LPS levels, cognitive function, and neuroimaging biomarkers. Sample size calculations based on 80% power to detect 0.4 effect size difference in LPS levels between groups (α=0.05).
Expected Outcomes
AD patients will exhibit significantly reduced microbiome diversity (Shannon index 20-30% lower, p<0.01) and increased abundance of LPS-producing Enterobacteriaceae compared to controls
Serum LPS levels will be 2-3 fold higher in AD patients versus controls (mean difference >150 pg/mL, p<0.001) and correlate positively with cognitive decline (r>0.4, p<0.01)
Probiotic intervention will reduce serum LPS by 25-40% from baseline (p<0.05) and slow cognitive decline by 30% compared to placebo group as measured by ADAS-Cog scores
Gut permeability markers (zonulin) will correlate with brain amy
...
AD patients will exhibit significantly reduced microbiome diversity (Shannon index 20-30% lower, p<0.01) and increased abundance of LPS-producing Enterobacteriaceae compared to controls
Serum LPS levels will be 2-3 fold higher in AD patients versus controls (mean difference >150 pg/mL, p<0.001) and correlate positively with cognitive decline (r>0.4, p<0.01)
Probiotic intervention will reduce serum LPS by 25-40% from baseline (p<0.05) and slow cognitive decline by 30% compared to placebo group as measured by ADAS-Cog scores
Gut permeability markers (zonulin) will correlate with brain amyloid burden on PET imaging (r>0.3, p<0.05) and predict cognitive decline over 24 months
Microbiome metabolomic analysis will identify 15-25 differentially abundant metabolites in AD patients, including reduced short-chain fatty acids and increased trimethylamine N-oxide
Intervention responders (>20% LPS reduction) will show preserved hippocampal volume and improved connectivity in default mode network on follow-up neuroimaging
Success Criteria
• Establish significant association between gut dysbiosis patterns and AD diagnosis with area under ROC curve >0.75 for microbiome-based classification model
• Demonstrate statistically significant correlation (p<0.01) between serum LPS levels and cognitive performance across all study timepoints
• Achieve primary endpoint of ≥25% reduction in LPS levels in probiotic group compared to placebo at 12 months with p<0.05
• Show significant between-group difference (p<0.05) in rate of cognitive decline favoring probiotic intervention by ≥2 points on ADAS-Cog scale
• Identify at least 10 ba
...
• Establish significant association between gut dysbiosis patterns and AD diagnosis with area under ROC curve >0.75 for microbiome-based classification model
• Demonstrate statistically significant correlation (p<0.01) between serum LPS levels and cognitive performance across all study timepoints
• Achieve primary endpoint of ≥25% reduction in LPS levels in probiotic group compared to placebo at 12 months with p<0.05
• Show significant between-group difference (p<0.05) in rate of cognitive decline favoring probiotic intervention by ≥2 points on ADAS-Cog scale
• Identify at least 10 bacterial species significantly associated with AD status (FDR-corrected p<0.05) that replicate across validation cohorts
• Demonstrate mechanistic pathway linking specific microbial taxa to LPS production, systemic inflammation, and neuroinflammation biomarkers with effect sizes >0.3